The regulatory system in Europe with special emphasis on allergen products

International Archives of Allergy and Immunology

Volumn 147, Issue 4, 2008, Pages 263-275

  Lorenz, A R ^a   Luttkopf D ^a   Seitz, R ^a   Vieths, S ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Allergen products; Marketing authorisation; Medicinal products; Regulatory affairs

Indexed keywords

ALLERGEN; ALUTARD AVANZ; GRASS POLLEN EXTRACT; GRASS POLLEN VACCINE; IMMUNOGLOBULIN E ANTIBODY; RECOMBINANT ALLERGEN; UNCLASSIFIED DRUG;

ALLERGY TEST; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTACT DERMATITIS; DOCUMENTATION; DRUG CONTROL; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; EUROPEAN UNION; GOOD MANUFACTURING PRACTICE; GOVERNMENT REGULATION; HUMAN; IMMUNOTHERAPY; INTRACUTANEOUS TEST; LEGAL LIABILITY; LYOPHILISATE; MEDICAL LITERATURE; MEDICAL SOCIETY; NONHUMAN; PHARMACY AND THERAPEUTICS COMMITTEE; PLASTER CAST; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHINOCONJUNCTIVITIS;

ALLERGENS; ANIMALS; CLINICAL TRIALS AS TOPIC; DNA, RECOMBINANT; DRUG AND NARCOTIC CONTROL; EUROPE; GUIDELINES AS TOPIC; HUMANS; IMMUNOTHERAPY; LEGISLATION, DRUG; PHARMACOPOEIAS AS TOPIC;

EID: 47549083156     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000146074     Document Type: Review

References (57)

1. Consolidated versions of the Treaty on European Union and of the Treaty establishing the European Community. OJ 2006;C321E:1-331.
2. Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. OJ 2004;L311:67-122.
3. Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products. OJ 1965;22:369-373.
4. Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products. OJ 2001;L311:1-66.
5. Directive 2004/27/EC of the European Parliament and the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. OJ 2004;L136:34-57.
6. Directive 2004/28/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/82/EC on the Community code relating to veterinary medicinal products. OJ 2007;L136:58-84.
7. Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. OJ 2003;L159:46-94.
8. EudraLex: The rules governing medicinal products in the European Union. http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/index.htm.
9. Regulation (EC) No. 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. OJ 2004;L136:1-33.
10. Guideline: Production and quality control of medicinal products derived by recombinant DNA technology. 1994;3AB1a.
11. Committee for Proprietary Medicinal Products (CPMP) and Biotechnology Working Party (BWP): Note for Guidance on Allergen Products. 1996;CPMP/BWP/243/96.
12. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic Q5B/Note for Guidance on quality of biotechnological products:analysis of the expression construct in cell lines used for production of r-DNA derived protein products. 2005;CPMP/ICH/139/95.
13. Committee for Proprietary Medicinal Products (CPMP): Points to consider on the reduction, elimination or substitution of Thiomersal in vaccines. 2001;CPMP/BWP/2517/00.
14. Bundesministerium für Gesundheit: Allgemeine Verwaltungsvorschrift zur Durchführung des Arzneimittelgesetzes (AMGVwV). BAnz 2006;63:2287-2289.
15. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Paul-Ehrlich-Institut: 3. Bekanntmachung zur klinischen Prüfung von Arzneimitteln am Menschen - Gemeinsame Bekanntmachung des Bundesinstitutes für Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts vom 10. August 2006. BAnz 2006;166:6072.
16. European Directorate for the Quality of Medicines (EDQM): II. Introduction; in Council of Europe (ed): European Pharmacopoeia. Strasbourg, ed 6, 2008, pp v-vii.
17. Heads of Medicines Agencies (HMA). http://www.hma.eu/.
18. European Medicines Agency (EMEA). http://www.emea.europa.eu/.
19. Seitz R: EU procedures for marketing authorization of pharmaceutical products. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2006;95:60-63.
20. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC and Regulation (EC) No. 726/2004. OJ 2006;L378:1-19.
21. Regulation (EC) No. 1902/2006 of the European Parliament and of the Council of 20 December 2006 amending Regulation 1901/2006 on medicinal products for paediatric use. OJ 2006;L378/20:1-2.
22. Committee for Medicinal Products for Human Use (CHMP): Committee for Medicinal Products for Human Use - Rules of Procedure. 2004;EMEA/CHMP/111481/ 2004.
23. Guideline on the definition of a potential serious risk to public health in the context of Article 29(1) and (2) of Directive 2001/83/EC - March 2006 (2006/C 133/05). OJ 2006; C133:5-7.
24. European Medicines Agency (EMEA), Committee for Medicinal Products for Human Use (CHMP), and Biologics Working Party (BWP): Mandates, objectives and rules of procedure for the CHMP Biologics Working Party (BWP). 2005;EMEA/CHMP/BWP/206296/2004.
25. Committee for Medicinal Products for Human Use (CHMP) and Biologics Working Party (BWP): Concept Paper on the revision of the Note for Guidance on Allergen Products (CPMP/BWP/243/96): production and quality issues. 2005;Doc.Ref.:CHMP/BWP/229472/2005.
26. European Medicines Agency (EMEA) and Committee for Medicinal Products for Human Use (CHMP): Mandate, objectives and rules of procedure for the CHMP Scientific Advisory Group on Cardiovascular Issues (SAG-CVS). 2007;EMEA/CHMP/337299/2005.
27. European Medicines Agency (EMEA) and Committee for Medicinal Products for Human Use (CHMP): Mandate, objectives and rules of procedure for the CHMP Scientific Advisory Group on Anti-Infectives (SAGAI). 2004;EMEA/CHMP/159394/ 2004.
28. Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human [CMD(h)]: Best Practice Guide for MRP. http://heads.medagencies.org/ index.html.
29. Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human [CMD(h)]: Best Practice Guide for the Reference Member State in the Mutual Recognition and Decentralised Procedures. http://heads.medagencies.org/ index.html.
30. Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human [CMD(h)]: Decentralised Procedure: Member States' Standard Operation Procedure. http://heads.medagencies.org/index.html.
31. European Medicines Agency (EMEA) and Co-ordination Group for Mutual Recognition and Decentralised Procedures - Veterinary [CMD(v)]: Best Practice Guide for Veterinary Decentralised Procedure (DCP), ed 01. 2007;EMEA/CMD(v)/ 63793/2006.
32. EudraLex Volume 2: Notice to Applicants. http://ec.europa.eu/enterprise/ pharmaceuticals/eudralex/homev2.htm#2a.
33. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. OJ 1998;L331:1-37.
34. European Directorate for the Quality of Medicines (EDQM): Monograph: Allergen Products - Producta allergenica; in Council of Europe (ed): European Pharmacopoeia. Strasbourg, ed 6, 2008, pp 679-680.
35. Committee for Medicinal Products for Human Use (CHMP) and Efficacy Working Party (EWP): Guideline on the clinical development of medicinal products for the treatment of allergic rhino-conjunctivitis. 2004;CHMP/EWP/2455/02.
36. Committee for Proprietary Medicinal Products (CPMP) and Efficacy Working Party (EWP): Note for Guidance on the clinical investigation of medicinal products in the treatment of asthma. 2002;CPMP/EWP/2922/01.
37. Lorenz AR, Lüttkopf D, May S, Scheurer S, Vieths S: The principle of homologous groups in regulatory affairs of allergen products - a proposal. Int Arch Allergy Immunol 2009; in press.
38. European Medicines Agency (EMEA), Committee for Medicinal Products for Human Use (CHMP), and Biologics Working Party (BWP): Draft: Guideline on allergen products: production and quality issues. 2007;EMEA/CHMP/BWP/304831/ 2007.
39. Committee for Medicinal Products for Human Use (CHMP) and Efficacy Working Party (EWP): Concept Paper on the preparation of a guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. 2006;EMEA/CHMP/EWP/18504/2006.
40. Committee for Medicinal Products for Human Use (CHMP): Draft: Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. 2007;Doc.Ref.CHMP/EWP/18504/2006.
41. European Medicines Agency (EMEA), Committee for Medicinal Products for Human Use (CHMP), and Efficacy Working Party (EWP): Mandate, objectives and rules of procedure for the CHMP Efficacy Working Party. 2004;EMEA/CHMP/EWP/ 139722/ 2004.
42. Council Directive 89/342/EEC of 3 May 1989 extending the scope of Directives 65/65/EEC and 75/319/EEC and laying down additional provisions for immunological medicinal products consisting of vaccines, toxins or serums and allergens. OJ 1989;L142:14-15.
43. Lidholm J, Ballmer-Weber BK, Mari A, Vieths S: Component-resolved diagnostics in food allergy. Curr Opin Allergy Clin Immunol 2006;6:234-240.
44. Heiss S, Mahler V, Steiner R, Spitzauer S, Schweiger C, Kraft D, Valenta R: Component-resolved diagnosis (CRD) of type I allergy with recombinant grass and tree pollen allergens by skin testing. J Invest Dermatol 1999;113:830-837.
45. van Hage-Hamsten M, Pauli G: Provocation testing with recombinant allergens. Methods 2004;32:281-291.
46. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O: Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608-613.
47. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, Reisinger J, Pelzmann M, Hayek B, Kronqvist M, Gafvelin G, Gronlund H, Purohit A, Suck R, Fiebig H, Cromwell O, Pauli G, van Hage-Hamsten M, Valenta R: Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004;101(suppl 2):14677-14682.
48. Valenta R, Niederberger V: Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007;119:826-830.
49. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic S6C/Note for Guidance on quality of biotechnological products:stability testing of biotechnological/ biological products. 1995;CPMP/ICH/138/95.
50. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic Q5D/Note for Guidance on quality of biotechnological products:derivation and characterisation of cell substrates used for production of biotechnological/biological products. 1997;CPMP/ICH/294/95.
51. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic Q6B/Note for Guidance on specifications:test procedures and acceptance criteria for biotechnological/ biological products. 1999;CPMP/ICH/365/96.
52. Committee for Proprietary Medicinal Products (CPMP) and Biotechnology Working Party (BWP): Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance: quality issues. 2003;EMEA/CPMP/BWP/3207/00/Rev1 .
53. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic S6/Note for Guidance on preclinical safety evaluation of biotechnology-derived pharmaceuticals. 1998;CPMP/ICH/302/95.
54. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic S2A/Note for Guidance on genotoxicity: Guidance on specific aspects of regulatory genotoxicity tests for pharmaceuticals. 1995;CPMP/ICH/141/95.
55. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic E8/Note for Guidance on general considerations for clinical trials. 1998;CPMP/ICH/291/95.
56. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of Good Clinical Practice in the conduct of clinical trials on medicinal products for human use. OJ 2001;L121:34-44.
57. Commission Directive 2005/28/EC of 8 April 2005 laying down the principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products. OJ 2005;L91:13-19.